Moderna Says Dosing Started in Pediatric Study of Covid Vaccine

Epigraph:

Every human life is precious and sacred. One who saves a life it is as if he or she has saved the whole of humanity. (Al Quran 5:32/33)

Source: WSJ

Moderna Inc. has begun studying its Covid-19 vaccine in children aged six months to 11 years in the U.S. and Canada, the latest effort to widen the mass-vaccination campaign beyond adults.

The Cambridge, Mass. company said Tuesday that the first children have received doses in the study, which Moderna is conducting in collaboration with the National Institute of Allergy and Infectious Diseases and a division of the Department of Health and Human Services.

“This pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population,” Moderna Chief Executive Stéphane Bancel said.

The bulk of the U.S. Covid-19 vaccination campaign so far has focused on protecting adults, who are at higher risk of severe disease caused by the coronavirus than children. Moderna’s and Johnson & Johnson ’s vaccines are authorized for use in adults 18 and older, while the vaccine from Pfizer Inc. and BioNTech SE is cleared for use in people 16 and older.

Efforts have begun to test the Covid-19 vaccines in children, who can still become infected, both to protect them from the virus and further build the population-level immunity to move past pandemic restrictions.

Read further

Categories: Vaccine

1 reply

  1. The phase 2-phase 3 trial is being conducted in conjunction with the National Institute of Allergy and Infectious Diseases, the company said in a statement on Tuesday. The study is expected to enroll approximately 6,750 participants in the U.S. and Canada.

    The two-part study will look at three doses in the youngest children and two doses in older kids in its first phase. An interim analysis will be conducted to determine what dose will be used in the second part of the study. Kids who receive the vaccine will be followed for 12 months.

    “This pediatric study will help us assess the potential safety and immunogenicity of our Covid-19 vaccine candidate in this important younger age population,” Moderna Chief Executive Officer Stephane Bancel said.

    https://www.bloomberg.com/news/articles/2021-03-16/moderna-says-dosing-started-in-pediatric-study-of-covid-vaccine?srnd=premium&sref=eGA8az79

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.